Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges

Recent phase II trials have shown that BRAF/MEK inhibitors and immune checkpoint inhibitors are active in patients with melanoma brain metastases (MBM), reporting intracranial disease control rates of 50–75%. Furthermore, retrospective analyses suggest that combining stereotactic radiosurgery with i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Clin Dermatol
Autori principali: Kuske, Marvin, Rauschenberg, Ricarda, Garzarolli, Marlene, Meredyth-Stewart, Michelle, Beissert, Stefan, Troost, Esther G. C., Glitza, Oliva Isabella Claudia, Meier, Friedegund
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2018
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6061393/
https://ncbi.nlm.nih.gov/pubmed/29417399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40257-018-0346-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi